Logo

Pfizer Received EC’s Conditional Marketing Authorization for Elerexfio for the Treatment of Relapsed and Refractory Multiple Myeloma

Share this
Pfizer

Pfizer Received EC’s Conditional Marketing Authorization for Elerexfio for the Treatment of Relapsed and Refractory Multiple Myeloma

Shots:

  • The EC has granted CMA based on cohort A of the P-II (MagnetisMM-3) study evaluating Elrexfio on patients (n=123) who received 3 prior therapies incl. an immunomodulatory agent, a proteasome inhibitor & an anti-CD38 Ab
  • The result of the study showed an ORR of 61% with a 71% chance of sustaining the response at 15 mos. After 24 wks. of weekly therapy, the findings additionally supported Q2W dosing for all responding patients. After switching for at least 6 mos. before the data cut-off date (n = 50), 38% achieved CR, & 80% of patients maintained their response
  • Elrexfio is bispecific antibody (BsAb) immunotherapy targeting BCMA and CD3. It binds to BCMA on myeloma cells and CD3 on T-cells, triggering T-cell activation to eliminate myeloma cells

Ref: Pfizer | Image: Pfizer

Related News:- Pfizer and BioNTech Reports P-I/II Study Result of mRNA-Based Combination Vaccine Program Against Influenza and COVID-19

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Kritika Jha

Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions